From June 9 – 13, ASCO’s delegates will participate in the American Medical Association’s (AMA) Annual Meeting of the House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA, and meets twice a year to discuss pressing issues and establish association policies. ASCO currently sends three delegates to the AMA HOD: Edward P. Balaban, DO, FACP, FASCO; Thomas A. Marsland, MD, FASCO; and Ray D. Page, DO, PhD, FACOI.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On June 8, 2018, the Food and Drug Administration granted regular approval to venetoclax (VENCLEXTA®, AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
ASCO has officially endorsed a statement by the 70 National Cancer Institute (NCI)-designated cancer centers calling for increased HPV vaccination and screening to eliminate human papillomavirus (HPV)-related cancers. The full uptake of the vaccine and screening could prevent 12,000 cervical cancers and nearly 40,000 other HPV-related cancers (oropharyngeal, anal, penile, vulvar, and vaginal cancers) among men and women annually in the United States.
On June 7, a new article published in JCO Clinical Cancer Informatics, “Applied Informatics Decision Support Tool for Mortality Predictions in Patients With Cancer,” reports on a prediction model the authors developed to identify patients with high mortality risk prior to the start of treatment regimens.
On June 4, 2018, the Food and Drug Administration approved Fulphila (pegfilgrastim-jmdb, Mylan GmbH) as a biosimilar to Neulasta (pegfilgrastim, Amgen, Inc.) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
On June 6, 2018, the One Voice Against Cancer Coalition (OVAC) will hold an “Online Day of Action” to advocate for increased funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
Today at the 2018 ASCO Annual Meeting, National Cancer Institute (NCI) Director Norman Sharpless, MD, announced $10 million in new funding for the National Clinical Trials Network (NCTN). ASCO applauds Dr. Sharpless' leadership in ensuring NCI's continued commitment to clinical trials, which expand our knowledge of cancer and offer the best treatment options for many patients.
As nearly 40,000 oncology professionals from around the world gather in Chicago for the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) to learn about the latest in clinical cancer research — from new treatment options and advances in precision medicine to insight for improving access to care — ASCO welcomes the U.S. Food and Drug Administration's (FDA) announcement that it is advancing new policies to make the drug review and approval process more modern, more scientifically rigorous, and more efficient.
ASCO is surveying oncology providers on how and when they initiate conversations about weight management, as well as help their patients achieve and maintain a healthy weight after a cancer diagnosis.
Researchers can access a wide array of ASCO data through the society’s Center for Research and Analytics (CENTRA). A detailed list of the data, along with samples of each dataset, can be found on CENTRA’s updated Data Library page.
A team of oncology professionals from the New Mexico Cancer Care Alliance and University of New Mexico Comprehensive Cancer Center who are currently participating in ASCO’s Quality Training Program turned their program project into a poster that was showcased at the Alliance for Clinical Trials in Oncology’s Spring Group Meeting held May 10–11.
In the last decade there has been widespread adoption of clinical pathways in the United States healthcare delivery system. A high-quality oncology clinical pathway is a detailed, evidence-based protocol for delivering cancer care, including but not limited to anticancer drug regimens for specific patient populations.
In 2017, providers and practices across the country began to implement the Quality Payment Program (QPP). Established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), QPP is changing the way physicians are reimbursed for services provided under Medicare Part B.
With Congress having recently passed federal "right-to-try" (RTT) legislation, ASCO has developed a suite of educational resources that will help members understand the impact of this law on cancer care and individuals with cancer. Resources include a podcast with guest ASCO Senior Vice President and Chief Medical Officer Dr. Richard Schilsky, FACP, FASCO, FSCT, an issue brief on RTT legislation, and an FAQ for oncologists and their patients.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to a proposed rule to revise the agency’s methods for assuring patient access to Medicaid services. In a letter to CMS Administrator Seema Verma, ASCO President Bruce Johnson, MD, FASCO, urged CMS to maintain its rule requiring states to monitor and report on beneficiary access to providers, and to ensure that final changes do not jeopardize access to care for patients with cancer. ASCO also encouraged CMS to explicitly require state assessment of access to oncologists.